Comparing Two Imaging Scans for Liver Cancer Screening
Compares ultrasound with abbreviated MRI to find liver cancer in adults at risk.
Plain-language title generated from the registry record
Registry title: Improving Hepatocellular Carcinoma Screening
Key facts
- Where
- Lausanne, SwitzerlandSee the site
Where in Switzerland
- Lausanne University HospitalLausanne, SwitzerlandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Naik Vietti Violi
- Trial code
- NCT05828446
- Record updated
- 2 November 2026
- Original description
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI.Read full original descriptionShow less
Prospective Comparison of Diagnostic Performance and Cost-effectiveness of US and Abbreviated MRI for Hepatocellular Carcinoma Screening
This is a monocentric, single blind, interventional, single arm study. It is designed to compare the rates of detection of hepatocellular carcinoma (HCC) by ultrasound (US) used in clinical routine vs. abbreviated magnetic resonance imaging (AMRI). The hypothesis is that dynamic AMRI with extracellular contrast agent injection has a higher patient-level detection rate of HCC than screening US and non-contrast AMRI.
Interested and eligible patients will be enrolled and undergo HCC screening rounds including US +/- contrast-enhanced US (clinical routine) and screening MRI within the same week bi-annually.
Inclusion: All adult patients with chronic liver disease and indication for HCC screening according to the European Association for the Study of the Liver recommendations; Informed Consent signed by the subject.
Exclusion: Prior liver nodule categorized as LI-RAD 4, 5 or M; History of HCC; History of other malignancy; History of liver transplantation; Any other condition making the patient unsuitable for the study; Patient's refusal of transmission of relevant medical conditions found on the medical examinations performed during the study; Pregnancy; MRI or MRI contrast agent precaution.